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Background. 18F-NaF positron emission tomography (PET) targets microcalciﬁcations. We
compared in vitro microPET assessed 18F-NaF uptake between culprit and non-culprit human
carotid plaques. Furthermore, we compared 18F-NaF uptake with calciﬁcation visualized on
microcomputed tomography (microCT).
Methods. Carotid plaques from stroke patients undergoing surgery were incubated in 18F-
NaF and scanned using a microPET and a microCT scan. The average PET assessed 18F-NaF
uptake was expressed as percentage of the incubation dose per gram (%Inc/g). 18F-NaF PET
volume of interest (VOI) was compared with CT calciﬁcation VOI.
Results. 23 carotid plaques (17 culprit, 6 non-culprit) were included. The average 18F-NaF
uptake in culprit carotid plaques was comparable with the uptake in non-culprit carotid plaques
(median 2.32 %Inc/g [IQR 1.98 to 2.81] vs. median 2.35 %Inc/g [IQR 1.77 to 3.00], P=0.916).
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Only a median of 10% (IQR 4 to 25) of CT calciﬁcation VOI showed increased 18F-NaF uptake,
while merely a median of 35% (IQR 6 to 42) of 18F-NaF PET VOI showed calciﬁcation on CT.
Conclusions. 18F-NaF PET represents a different stage in the calciﬁcation process than CT.
We observed a similar PET assessed 18F-NaF uptake and pattern in culprit and non-culprit
plaques of high-risk patients, indicating that this method may be of more value in early
atherosclerotic stenosis development. (J Nucl Cardiol 2018)
Spanish Abstract
Antecedentes. La tomografía por emisión de positrones (PET) con 18F-ﬂoruro de sodio
(18F-NaF) demuestra microcalciﬁcaciones. En este estudio, comparamos la captación de
18F-NaF entre placas carotideas culpables y no culpables valorada con microPET in vitro.
Además, comparamos la captación de 18F-NAF con las calciﬁcaciones detectadas por microto-
mografía computada (microCT).
Métodos. Placas carotídeas de pacientes postoperados que sufrieron de un evento vascular
cerebral fueron incubadas en 18-NaF y escaneadas usando microPET y microCT. El promedio
de la captación fue expresado como porcentaje de la dosis de incubación por gramo (%Inc/gr).
El volumen de interés (VOI) del PET 18F-NaF se comparó con el VOI de calciﬁcación por CT.
Resultados. Se incluyeron 23 placas carotídeas (17 culpables y 6 no culpables). El promedio
de la captación de 18F-NaF en placas carotídeas culpable fue comparable al de las placas no
culpables. (mediana 2.32%Inc/gr [IQR1.98-2.81] vs. mediana 2.35%Inc/gr [IQR1.77-3], p=.916).
Solo una mediana de 10% (IQR 4-25) del VOI en CT mostró un aumento en la captación de 18F-
NaF, mientras una mediana de 35% (IQR 6-42) del VOI de PET 18F-NaF mostró calciﬁcación en
CT.
Conclusiones. La tomografía por emisión de positrones con 18F-NaF evalúa una etapa
distinta en el proceso de calciﬁcación que la CT. El patrón de captación de 18F-NaF que
observamos en este estudio fue similar entre placas culpables y no culpables de pacientes de alto
riesgo, lo cual indica que este método puede ser de mayor valor en el desarrollo temprano de la
estenosis ateroesclerótica. (J Nucl Cardiol 2018)
Chinese Abstract
背景. F18 氟化钠正电子发射断层扫描 (PET) 可用于检测微钙化。我们使用微型 PET 来
评估病人体外 F18 氟化钠在颈动脉罪犯和非罪犯斑块之间的的摄取区别。此外, 我们还将 F18
氟化钠的摄取与 microCT 扫描检测的钙化进行对比。
方法. 将接受手术的中风患者的颈动脉斑块在 F18 氟化钠中培养并用 microPE 和
microCT 进行扫描。PET 对 F18 氟化钠的平均摄取率表示为每克培养剂量的百分比。F18 氟
化钠 PET 中的感兴趣区域和 CT 钙化图像中的感兴趣区域 (VOI) 进行比较。
结果. 一共有 23个颈动脉斑块, 其中 17个罪犯斑块和 6个非罪犯斑块。罪犯和非罪犯颈动
脉斑块的 F18氟化钠的平均摄取率无明显差异 (中值 2.32 % Inc/g [IQR 1.98-2.81] vs.中值2.35
% Inc/g [IQR 1.77-3.00], p = 0.916)。仅中值为10% [IQR 4-25]的 CT钙化 VOI显示有F18氟化
钠的摄取增加, 中值为 35%[IQR 6-42] 的 F18 氟化钠 PET VOI 显示有CT 上的钙化。
结论. 相较于 CT, F18氟化钠 PET展现了钙化过程中的一个不同阶段。在高危病人中,我
们观察到罪犯和非罪犯斑块具有类似的 PET F18 氟化钠摄取和模式, 表明该方法可能在早期
动脉粥样硬化狭窄发展中具有更高的价值。 (J Nucl Cardiol 2018)
French Abstract
Contexte. La tomographie par émission de positons (TEP) au 18F-NaF marque les micro-
calciﬁcations. Nous avons comparé in vitro les plaques carotidiennes humaines responsable
d’accident vasculaire cérébrales marquées au 18F-NaF avec une microTEP et leur calciﬁcation au
moyen d’un microCT
Méthodes. Les plaques carotidiennes de patients victimes d’un accident vasculaire cérébral
qui ont bénéﬁcié d’ une intervention chirurgicale ont été incubées dans du 18F-NaF et imagées
avec une microTEP et un microCT. Le pourcentage d’absorption moyen de 18F-NaF par gr de
tissu (% Inc/g) ont été comparées au volume d’intérêt (VOI) des calciﬁcations mesurées par CT.
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Résultats. 23 plaques carotidiennes (17 responsables d’un AVC et 6 non responsables) ont été
incluses. Le %moyen d’absorption de 18F-NaF dans les plaques carotidiennes responsables furent
comparable à l’absorption dans les plaques non responsables (2,32% Inc/g vs 2,35% Inc/g , p =
0,916). Dix pourcent seulement des calciﬁcations visualisées par CT démontrèrent une augmen-
tation d’absorption de 18F-NaF et 35% des plaques montrant une absorption de 18F-NaF PET VOI
démontrèrent des calciﬁcations au CT.
Conclusions. L’imagerie de l’absorption de 18F-NaF par tomographie à positrons représente
un processus physiopathologique différent de l’imagerie des calciﬁcations par CT. L’absorption du
18F-NaF par les plaques responsables et non responsables d’accidents vasculaire cérébraux
pourrait s’avérer utile dans le diagnostic précoce des sténoses athéromateuses. (J Nucl Cardiol
2018)
Key Words: 18F-sodium ﬂuoride (18F-NaF) · Calciﬁcation · PET/CT imaging · Vulnerable
atherosclerotic plaque · Carotid artery stenosis
Abbreviations
18F-NaF 18F- sodium fluoride
PET Positron emission tomography
CT Computed tomography
CEA Carotid endarterectomy
PBS Phosphate buffered saline
QMA Quarternary methyl ammonium
VOI Volume of interest
HU Hounsfield Unit
MSB Martinus Scarlet Blue
IQR Interquartile range
BMI Body mass index
INTRODUCTION
Surgical removal of atherosclerotic plaques from
the carotid artery highly reduces the risk of future stroke
in symptomatic patients with ≥70% stenosis.1 However,
most of these patients will not have a new event when
treated with best medical therapy.2 Furthermore, the role
of surgery in moderate symptomatic stenosis (50% to
69%) and asymptomatic stenosis is under debate.3–5
Therefore, taking into account the potential risk for
surgical complications, the selection of patients who will
benefit most from surgery is challenging.
In order to improve risk stratification, research has
been focused on the identification of plaques at risk for
rupture, so-called vulnerable plaques.6–8 Currently, pla-
que thickness and intraplaque processes, such as
inflammation and microcalcification, are seen as impor-
tant contributors to vulnerability. These processes have
become targets of various molecular imaging techniques,
as they potentially allow non-invasive risk stratification of
individual patients with carotid artery stenosis.9,10
Recently, several studies have shown the feasibility of
18F-sodium fluoride (18F-NaF) positron emission tomog-
raphy (PET) for imaging of atherosclerotic plaques.11–13
18F-NaFpredominantly binds to areas ofmicrocalcification
within the plaque.14 Appearance of microcalcifications
indicates the active formation of calcification and is
associated with plaque vulnerability.15,16 In contrast,
established calcifications are seen as atherosclerotic end
stage products and are associatedwith plaque stability.17–20
It has been suggested that 18F-NaFmay additionally be
a usefulmarker for plaque vulnerability.21 Indeed, a clinical
study by Joshi et al. showed that ruptured and high-risk
coronary plaques have a significantly higher 18F-NaF
uptake than non-culprit and low-risk coronary plaques.22
However, data on 18F-NaF uptake in carotid plaques are
limited and their usefulness for the prediction of future
stroke is unclear.23–25 Additionally, limited data have been
publishedon the relationbetween activemicrocalcifications
and established calcifications in human carotid plaques.26,27
The primary objective of this study is to compare
in vitro microPET assessed 18F-NaF uptake between
culprit and non-culprit carotid plaques from stroke
patients, using non-macrocalcified renal arteries from
healthy kidney donors as negative controls. The sec-
ondary objective is to compare the distribution of 18F-
NaF uptake on microPET with calcification visualized
on a high-resolution microcomputed tomography (mi-
croCT) in carotid plaques.
MATERIALS AND METHODS
Study Subjects
Carotid plaques were collected from stroke patients who
underwent carotid endarterectomy (CEA) at the Department of
Surgery (Division of Vascular Surgery) of the University
Medical Center Groningen (UMCG), between July 2015 and
March 2016. Indication for CEA was decided by a surgeon
expert panel and was based on the presence of symptomatic
(culprit) stenosis (≥50%) or asymptomatic (non-culprit) steno-
sis (≥70%) of the internal carotid artery, according to internal
guidelines.28,29 One patient with\50% stenosis was selected
for CEA because of an irregular aspect of the plaque surface.
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In order to increase the reliability of our measurements,
we used renal artery specimens from healthy kidney donors as
negative controls. The specimens were obtained during living
donor nephrectomy.
Clinical and demographic data from the included patients
were collected from medical records. In the group with culprit
plaques, medication use and history of cardiovascular diseases
prior to the recent event were registered. The study was
reviewed by the ethics committee of the UMCG (METc 2015/
258). All patients gave written informed consent.
Study Procedure
Immediately after excision, carotid plaques and renal artery
specimens were placed into phosphate buffered saline (PBS) and
kept on ice. Both were incubated for one hour in 49.4±7.2 MBq
18F-NaF in 20 mL. After incubation, the plaques and renal
arteries were carefully rinsed 5 times with 10 mL PBS. Then,
tissue samples were weighed and microPET and microCT scans
were performed. After the imaging procedure, the carotid
plaques were cut transversely into segments of 3 to 4 mL. The
renal arteries had a maximum thickness of 5 mL and therefore
no cross-sections were made. The segments were embedded in
paraffin for histological analysis.
Production of 18F- NaF
18F-NaF was produced by passing a solution of 18F-fluoride
in water over a quaternary methyl ammonium (QMA) light
anion exchange cartridge (Waters Chromatography B.V., Etten-
Leur, The Netherlands). After washing the QMA with water,
[18F]-fluoride was eluted with saline and passed over a sterile
Millex GS 0.22 µm filter (Millipore B.V., Amsterdam, The
Netherlands). The radiochemical purity for all runs was[95%.
PET and CT Acquisition
Carotid plaques and renal arteries were positioned into a
microPET scanner (MicroPET Focus 220, Siemens Medical
Solutions USA, Knoxville, TN, USA), and an emission scan of
30 minutes was performed. After the PET scan was finished, the
bed of the PET scanner was transferred to a microCT scanner
(Inveon CT, Siemens Medical Solutions USA, Knoxville, TN,
USA) without moving or touching the tissue samples. The CT
exposure settings were 50 keV and 500 µAs, and a 100-ms
exposure time for 360 projections during one 360° rotation.
The PET scans were reconstructed into a single frame of
30 minutes, using OSEM2D (4 iterations and 16 subsets), after
being normalized and corrected for attenuation and decay of
radioactivity. The CT images were reconstructed with the
Feldkamp algorithm.30
Data Analysis
The PET and CT images were automatically registered
using PMOD 3.7 (PMOD Technologies LLC, Zu¨rich, Switzer-
land). The registration was visually inspected and manually
corrected when necessary. For quantification of the average
18F-NaF uptake, three-dimensional volumes of interest (VOIs)
were drawn around the whole tissue samples. The uptake (in
kBq/cc) was corrected for weight of the specimen and the
incubation dose, and expressed as percentage uptake of total
incubation dose per gram of tissue (%Inc/g). It was assumed
that 1 cubic centimeter equals 1 gram of tissue.
VOIs were also automatically drawn around 18F-NaF PET
areas with a threshold of ≥50% of the maximum 18F-NaF uptake
and assigned as 18F-NaF PET VOI. VOIs were automatically
drawn around CT areas with a Hounsfield Unit (HU) ≥1000 and
assigned as CT calcification VOI. The threshold of 50% of the
maximum uptake value was chosen in order to select the volume
with the highest 18F-NaF uptake, and thereby minimize the bias
of a partial volume effect.27 The HU of 1000 was based on the
CT scan of a phantom with various known calcium hydroxya-
patite densities, whereby a lower threshold was chosen in order
to not miss any calcification. To determine the overlap between
the 18F-NaF PET VOIs and CT calcification VOIs, an intersec-
tion VOI was automatically drawn. Then, the CT calcification
area (HU≥1000) within the 18F-NaF PET VOI was measured
and expressed as a percentage of the 18F-NaF PET VOI; and the
other way around; 18F-NaF PET uptake area (≥50% of maximum
18F-NaF uptake) within the CT calcification VOI was measured
and expressed as a percentage of the CT calcification VOI.
Histological Staining
To validate our data, von Kossa and alizarin red stainings
for calcification were performed on two plaque segments
without any CT calcification, but with clear 18F-NaF uptake.
The pattern of 18F-NaF uptake on PET images was compared
with the results of histology. Furthermore, the two renal
arteries with the highest 18F-NaF uptake were selected for
staining (negative controls). Only negligible 18F-NaF uptake
was expected and no calcification in the renal arteries, because
only healthy kidney donors with a renal vasculature without
any signs of atherosclerosis are eligible for transplantation.
To obtain further information on the vulnerability of
included carotid plaques, segments of five culprit and three
non-culprit plaques were assessed for histological features of
vulnerability. The segments were stained with Martius Scarlet
Blue (MSB) using histochemistry and for CD68- and CD34-
expressing cells using immunohistochemistry.31 With these
markers, the presence of intraplaque thrombus and collagenous
fibrous cap (MSB), inflammation (CD68-positive macro-
phages), and intraplaque microvessels (CD34-positive
endothelial cells) could be identified. One observer, highly
experienced in vascular pathology, visual inspected and
interpreted the histological features, and compared the culprit
and non-culprit plaques. For a detailed description of the
staining procedures, see Online Resource 1.
Statistical Analysis
Descriptive data are presented as frequencies (percent-
age), median (interquartile range), or mean± SD. Based on the
distribution of data (tested by normal probability plots),
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differences between data were analyzed with non-parametric
tests. For continuous data the Mann–Whitney U test (two
groups) or the Kruskal–Wallis test (≥ two groups) was used.
Categorical data were analyzed with the Chi Square test. A
Spearman Correlation was used to test the association between
continuous data. A two-sided P-value <0.05 was considered
statistically significant. Statistical analyses were performed
using SPSS for Windows (version 23.0).
RESULTS
Patient Characteristics
We included 23 carotid plaques (17 culprit and 6 non-
culprit) from 23 patients (median age 72 years, interquar-
tile range [IQR] 61 to 75, 85% male) who had undergone
CEA, and 15 renal artery specimen from healthy kidney
donors (Table 1). The demographic and clinical charac-
teristics were comparable between stroke patients with
culprit and non-culprit plaques (Table 2). Only BMI was
higher in the non-culprit group (P=0.020). Themean time
between the cerebrovascular event (stroke, TIA or amau-
rosis fugax) and CEA in the group with culprit plaques
was 21±14 days. All patients in the non-culprit group had
a history of stroke related to the contralateral carotid
artery. The time range between that stroke and the recent
non-culprit CEA was 2 to 23 months. The healthy kidney
donors (from whom renal artery segments were obtained)
were younger than CEA patients (P=0.001) and had no
history of cardiovascular disease.
Visual Assessment of PET and CT Images
PET images of all 23 plaques, showed a heteroge-
neous 18F-NaF uptake distribution and clear hotspots
(Figure 1). The registered PET and CT images (n=16)
showed a discordant pattern between CT assessed calci-
fication and 18F-NaF PET assessed calcification. In all
plaques, 18F-NaF uptake was seen in regions without
calcifications visualized on CT scan. In the largest CT
calcification volumes 18F-NaF uptake was only seen at the
outer surface (Figure 2). The 18F-NaF uptake in the renal
arteries was only visible when a low 18F-NaF uptake
threshold was chosen compared with the carotid plaques,
and no calcification was visible on the CT (n=8).
18F-NAF UPTAKE IN CULPRIT AND NON-
CULPRIT PLAQUES
The average 18F-NaF uptake was similar in culprit
and non-culprit carotid plaques (median 2.32 %Inc/g
[IQR 1.98 to 2.81] vs. median 2.35 %Inc/g [IQR 1.77 to
3.00], P=0.916), while the uptake in carotid plaques was
significantly higher than in renal arteries (median 2.32 %
Inc/g [IQR 1.86 to 2.80] vs. median 0.44 %Inc/g [IQR
0.18 to 0.68], P\0.001) (Figure 3).
Comparison of 18F-NaF PET VOIs with CT
Calcification VOIs
The 18F-NaF PET VOIs of the carotid plaques had a
size of median 41 mm3 (IQR 20 to 74), consisting of
median 6% (IQR 3 to 10) of the total plaque volume
(Table 3). The binding of 18F-NaF in the 18F-NaF PET
VOIs was median 4.7 (IQR 3.9 to 6.2) %Inc/g (Table 4).
Overall, only a median of 35% (IQR 6 to 42) of the 18F-
NaF PET VOI areas consisted of CT assessed
calcification.
The CT calcification VOI had a size of median 149
mm3 (IQR 16 to 290), consisting of median 16% (IQR 3
to 27) of the total plaque volume (Table 3). The overall
binding of 18F-NaF in the CT calcification VOIs was
lower than in the 18F-NaF PET VOI (median 2.6 [IQR
1.9 to 3.2] %Inc/g) (Table 4). Overall, a median of 10%
(IQR 4 to 25) of the CT calcification VOI areas showed
18F-NaF uptake.
The averaged HU of the 18F-NaF PET VOIs
(median 901 HU [IQR 94 to 1349]) was lower than
that of the CT calcification VOIs (median 3258 HU
[IQR 2465 to 3616]), as these 18F-NaF PET VOIs
consist only partially of CT assessed calcification
(Table 4). In renal arteries no CT calcification VOI
could be detected; median HU of total renal artery
volume was -470 HU (IQR −530 to −390).
No significant association was found between 18F-
NaF uptake of the plaque (%Inc/g) and the CT calci-
fication VOI (r=0.382, P=0.144), although 18F-NaF
uptake seems to increase when CT calcification VOI
increases in most plaques (Figure 4).
Table 1. Included specimens
Culprit plaque Non-culprit plaque Renal artery specimen
Number included 17 6 15
Number PET performed 17 6 15
Number CT performed 15 1 8
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Histological Staining
The von Kossa and alizarin red stainings showed
calcification deposits in the two selected 18F-NaF-
positive, CT negative segments of the carotid plaques.
The pattern of 18F-NaF uptake on PET images matched
with the area of histologically proven calcification
(Online Resource Figure 1). Areas with negligible 18F-
NaF uptake did not show any histological evidence for
calcification. As expected, no calcifications were iden-
tified in the segments of the renal arteries (Online
Resource Figure 2).
The five culprit and three non-culprit plaques
segments showed all at least one characteristic of
vulnerability. Macrophage infiltration was clearly visi-
ble in all segments, as was the presence of intraplaque
microvessels, without a visual difference in culprit or
non-culprit segments. Two culprit plaques and one non-
culprit plaque showed a clear thrombus indicative of
intraplaque hemorrhage. One non-culprit plaque showed
a very thin fibrous cap (Online Resource Figure 3).
DISCUSSION
The present study investigated in vitro microPET
assessed 18F-NaF uptake, in culprit and non-culprit
human carotid plaques. We hypothesized that 18F-NaF
uptake in culprit plaques was higher than in non-culprit
carotid plaques, based on previous results in coronary
plaques, and the concept of microcalcification and
plaque rupture.15,22 Our results, however, demonstrate







Age (years) 72 (64–76) 71 (55–72) 55 (41–63)
Sex, male 14 (82) 5 (83) 5 (33)
Stenosis degree (%)
70–99 14 (82) 6 (100) –
50–69 2 (12) – –
\50 1 (6) – –
Presenting symptoms
Stroke 9 (53) – –
TIA 7 (41) – –
Amaurosis fugax 1 (6) – –
Cardiovascular history 8 (47) 6 (100) 0
Coronary artery disease 3 (18) 3 (50) –
Cerebrovascular diseasea 4 (24) 6 (100) –
Peripheral artery disease 4 (24) 2 (33) –
Diabetes mellitus 1 (6) 3 (50) 0
Current smoker 6 (34) 2 (33) 6 (40)
BMI (kg/m2) 25 (23–30) 31 (29–31) 26 (24–28)
SBP (mm Hg) 139 (132–150) 144 (127–173) 134 (127–148)
DBP (mm Hg) 76 (60–83) 73 (68–78) 76 (70–83)
Total cholesterol (mmol/L) 4.4 (3.5–6.1) 4.2 (3.4–10) 5.5 (4.8–6.2)
LDL cholesterol (mmol/L) 3 (2.2–3.8) 2.5 (2.0–8.2) 3.1 (2.7–4.1)
Medicationb
Antihypertensives 9 (53) 3 (50) 3 (20)
Statins 7 (41) 6 (100) 1 (6)
Antiplatelet therapy 5 (29) 6 (100) 0
Anticoagulation 3 (18) 0 0
Data are expressed as number (%) or median (interquartile range)
TIA, transient ischemic attack; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low-density
lipoprotein
aIn culprit plaques: other than current event
bIn culprit plaques: medication use prior to the recent cerebrovascular event
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comparable 18F-NaF uptake in culprit and non-culprit
carotid plaques. Interestingly, we found that 18F-NaF
uptake was present in regions without evidence of
calcification on CT scan. Furthermore, most of the CT
calcification VOIs had low 18F-NaF uptake, confirming
that both techniques represent a different stage of
calcification.14,23,32
Figure 2. Sagittal views of 18F-NaF microPET and microCT of human carotid plaques. (A, D, G)
PET areas with 18F-NaF uptake. (B, E, H) CT images showing calcification. In image B only one
small calcification can be seen in the areas of 18F-NaF uptake. (C, F, I) Fused images. Volumes of
interest are drawn around CT calcification areas (white calcification, pink line). The relatively large
calcifications (white arrows) show the most intense 18F-NaF uptake at their surface. In the smaller
calcifications this cannot be observed due to the limited resolution. Scale PET images in %Inc/g,
scale CT images in HU.
Figure 1. 18F-NaF microPET and microCT images of human carotid plaque. (A, E) Human carotid
plaque after carotid endarterectomy. (B, F) Sagittal view of ex vivo PET showing a heterogeneous
distribution of 18F-NaF uptake with a clear hotspot (red/yellow). (C, G) Sagittal view of
corresponding microCT images. On the background of example G are the contours of the CT bed
visible. (D, H) Fused images showing different distributions of microcalcification (18F-NaF PET)
and established calcification (microCT). Scale PET images in %Inc/g, scale CT images in HU.
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Recently, Vesey et al. showed that in vivo 18F-NaF
uptake was higher in culprit carotid artery stenosis than
in the contralateral non-culprit stenosis in 18 patients
with recent CVA (log10 standardized uptake value, mean
0.29±0.10 vs 0.23±0.11 respectively, P\0.001).23
These findings are consistent with the results of a
clinical study of Quirce et al., in nine patients, where
18F-NaF uptake reported as mean target-to-background
ratio was higher in culprit plaques (2.12±0.44) than in
contralateral non-culprit plaques (1.85±0.46, P=
0.220).24 Age and sex distribution were comparable
between these two studies and our study. Only Vesey
et al. provided information about the cardiovascular
history and other cardiovascular risk factors of the
included patients. The prevalence of smoking and
diabetes mellitus was similar. Furthermore, more than
50% of the patients had other manifestations of
atherosclerosis, as in our study. Since the included
patients in both studies were comparable, the remaining
question is how these contradictive results can be
explained.
Figure 3. 18F-NaF uptake, as measure of microcalcification, in
human carotid plaques and controls. PET assessed 18F-NaF
uptake in culprit and non-culprit carotid plaques. Renal arteries
of healthy kidney donors are used as negative controls. Data is
expressed as percentage 18F-NaF uptake of the total incubation
dose per gram of tissue (% Inc/g). The horizontal line
represents the median.
Table 3. Comparison of 18F-NaF PET VOI with CT calcification VOI






















1 74 15 1 2 0.4 21
2 53 6 38 202 22 10
3 130 2 37 143 13 34
4 12 2 33 86 13 4
5 20 2 14 146 17 2
6 36 4 50 319 33 6
7a 46 9 – – – –
8 71 9 43 342 41 9
9 21 2 38 156 18 5
10b 165 10 40 487 29 14
11 172 17 46 162 16 49
12 35 4 45 152 16 10
13 73 7 4 13 1 22
14 20 6 28 16 3 36
15 17 3 3 16 2 3
16 28 4 24 468 47 1
18F-NaF PET VOI was defined as ≥50% of maximum 18F-NaF uptake; CT calcification VOI was defined as Hounsfield Units ≥1000
VOI, volume of interest; PET, positron emission tomography; 18F-NaF, 18F- Sodium Fluoride; CT, computed tomography; HU,
Hounsfield Units
aIn this carotid plaque, no calcifications could be identified on CT scan
bNon-culprit carotid plaque
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First, although Vesey et al. did find a significant
difference between 18F-NaF uptake in culprit and
contralateral non-culprit plaques, the differences were
small and a substantial overlap between the uptake
values in both groups was present, as was in the study of
Quirce et al. Furthermore, the 18F-NaF uptake between
patients scheduled for CEA and control patients differed
to a larger extent (delta 0.17 SUVmean) than the
difference between culprit and non-culprit uptake (delta
0.07 SUVmean).
23 Therefore, we believe that no absolute
cut off value for the diagnosis of culprit plaques based
on 18F-NaF uptake can be determined, only when
compared with control patients there is a relevant
difference. This is in line with the results of our study.
Although the sample size is small, our data show that
18F-NaF uptake between culprit and non-culprit carotid
plaques was comparable while the uptake in plaques was
significantly higher than in control renal arteries.
Second, there may be differences in the degree of
stenosis of the carotid arteries between patients in the
aforementioned studies and our patients. Vesey et al.
found that 18F-NaF uptake was related to the degree of
stenosis on CT, but they did not report the stenosis
degree in the separate groups, neither did Quirce et al. In
our study, the stenosis degree in both, non-culprit and
the culprit plaques, was high and all plaques showed
high-risk features based on histology. This could explain
the similar 18F-NaF uptake.










1 3.6 1.9 −295 2273
2 5.9 2.5 1367 3616
3 4.8 3.7 1293 3489
4 7.6 3.0 603 3085
5 5.1 1.5 206 2769
6 5.8 2.8 1512 3616
7a 2.6 – −361 –
8 4.6 1.9 1140 3258
9 4.0 1.9 1242 3755
10b 4.4 2.8 1102 3312
11 3.8 3.2 1835 3645
12 6.2 3.2 1414 3115
13 3.4 2.6 57 2465
14 7.2 5.5 699 2152
15 4.1 1.5 −137 1885
16 6.5 2.6 568 3289
18F-NaF uptake was expressed as percentage uptake of total incubation dose per gram
18F-NaF, 18F- Sodium Fluoride; PET, positron emission tomography; CT, computed tomography; HU, hounsfield units; VOI, volume
of interest
(%Inc/g). 18F-NaF PET VOI was defined as ≥50% of maximum 18F-NaF uptake; CT calcification VOI was defined as Hounsfield Units
≥1000
aIn this carotid plaque, no calcifications could be identified on CT scan
bNon-culprit carotid plaque
Figure 4. Relation between PET assessed 18F-NaF uptake and
CT assessed calcification in human carotid plaques. CT
assessed calcification VOI was defined as HU-value ≥1000.
Data is expressed as percentage 18F-NaF uptake of the total
incubation dose per gram of tissue (% Inc/g). Spearman
Correlation was used to assess the relation between 18F-NaF
uptake and CT assessed calcification.
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In contrast, Joshi et al. did find a difference between
culprit and non-culprit coronary plaques of patients with
myocardial infarction.22 This might be the consequence
of local differences in the mechanical forces exerted to
the artery wall and the endothelium of the coronary
vascular bed, causing local differences in plaque initi-
ation and progression.33 In contrast to the coronary
arteries, both carotid arteries are exposed to similar
blood flow patterns and mechanical stress. This might
result in the same pattern of plaque development and
progression.
18F-NaF activity was increased in areas without
calcification on CT and most of the CT calcification VOI
showed minimal 18F-NaF uptake. This supports the idea
that microcalcification, as visualized with 18F-NaF PET,
and established calcification visualized on CT may
reflect different stages of the calcification processes in
atherosclerotic plaques.23,27,34
Established calcification is a well-known marker of
total plaque burden and is strongly associated with the
risk for cardiovascular events.35 However, the amount of
established calcification, as detected by CT, only pro-
vides information about the processes in the past and not
about the actual biological activity of the plaque.36
Moreover, larger and denser areas of calcification may
even stabilize the plaque.37 This has, for example, been
suggested by Shalaan et al., who found a higher CT
assessed calcification volume in non-culprit than in
culprit carotid plaques.38 The average percentage of
plaque volume that was calcified was comparable with
our study. Unfortunately, in our study CT assessed
calcification volume could not be compared between
culprit and non-culprit plaques, due to limited availabil-
ity of CT images in the non-culprit group (n=1) because
of image reconstruction failures.
Another important example can be derived from the
work of Puri et al., who performed a post-hoc patient-
level analysis of 8 prospective trials in which coronary
atheroma was measured with intravascular ultrasound.
They showed that although statins had a clear plaque-
regressive effect, they also promoted coronary atheroma
calcification, indicating stabilization.39
In this study increased 18F-NaF uptake was related
to the calcium volume on CT in the majority of the
carotid plaques. This is probably caused by binding of
18F-NaF at only the surface of the calcifications.14 The
binding of fluoride to hydroxyapatite is based on ion
exchange, rather than incorporation by active transport.
This probably also explains why 18F-NaF uptake can
still be found in vitro.
However, in our study a few plaques with low
calcium volume had a high 18F-NaF uptake and vice
versa. This suggests 18F-NaF accumulation in areas
without any evidence of calcification, or at least no
calcification with a size above the detection limit of the
microCT scan.14 The presence of calcifications smaller
than the CT detection limit, i.e. microcalcifications was
indeed confirmed by histological staining of 18F-NaF
positive and CT negative segements. 18F-NaF probably
binds to the relatively large surface of microcalcifica-
tions , causing an intense signal on PET images.14
These observations indicate that 18F-NaF imaging
can detect biologically active plaques, before they can
be visualized on CT. This implies that 18F-NaF imaging
may be useful in evaluating disease progression, as was
further shown in patients with aortic stenosis, where
baseline 18F-NaF uptake correlated well with the cal-
cium progression after 1 year.40 Especially, 18F-NaF
uptake in areas without established calcification on CT
was the best predictor of calcium progression.
Furthermore, Derlin et al. found a positive correla-
tion between 18F-NaF uptake in the carotid arteries and,
age and various cardiovascular risk factors in 269
patients with no history of stroke.32 Derlin et al.
included a heterogeneous population, consisting of
patients with low or minimal cardiovascular risk as
well. In contrast, we included only patients with already
a history of cardiovascular disease and, therefore, at a
high-risk for a cardiovascular event. These findings
further highlight the possibility of 18F-NaF imaging to
identify patients at high-risk for cardiovascular disease
in a low-risk population. In addition, the finding that
18F-NaF uptake in carotid plaques exceeded that of
controls (renal arteries) and no calcification was visible
in renal arteries on microCT or with histological staining
adds evidence to the hypothesis that the presence of
microcalcification identified by 18F-NaF is a feature of
atherosclerosis. The relation between the extent of 18F-
NaF uptake in bilateral carotid plaques and features of
vulnerability needs to be further investigated.
Strengths of our study are the inclusion of a control
group, and the scanning of calcium phantoms in order to
accurately determine the calcium threshold. Further-
more, by comparing calcification identified by 18F-NaF
PET imaging with calcification visualized on microCT,
this study adds knowledge to the relatively new field of
18F-NaF imaging in atherosclerosis. Our study has some
limitations. First, it should be considered that the
number of plaques, especially non-culprit plaques, is
small and a type II statistical error might be introduced.
However, given the similar distribution of 18F-NaF
uptake in both groups, a high number of plaques would
need to be recruited to find a statistical significant
difference if present. We believe that small differences
in uptake will not have any clinical implication.
Second, the tracer uptake could be underestimated
due to partial volume effects, as with every imaging
study. Third, CT images of 16 plaques (one non-culprit)
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out of 23 were available for analysis due to practical and
technical issues. Fourth, we did not assess the plaque
morphology of the right and left side in the same patient.
Culprit and non-culprit plaques were derived from
different patients.
NEW KNOWLEDGE GAINED
We have demonstrated that the calcification patterns
on 18F-NaF PET images and CT images are different.
Clearly, 18F-NaF PET visualizes a different stage of the
calcification process than CT. 18F-NaF uptake in carotid
plaques exceeded the uptake in non-calcified renal
arteries, but was comparable between culprit and non-
culprit carotid plaques, probably due to the advanced
nature of atherosclerotic disease in our patients.
CONCLUSION
We conclude that 18F-NaF has the potential to
identify carotid plaques with active calcification. Further
prospective studies on 18F-NaF uptake and symptoma-
tology are required to assess the predictive and
diagnostic value of 18F-NaF imaging in patients with
early stage atherosclerosis.
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